All questions
Safety: Xolair (omalizumab) in allergic asthma
8 questions · 3 sources
Safety questions that apply to every indication of Xolair are on Xolair (omalizumab), all indications: Safety.
Safety
Do patients develop antibodies to Xolair in asthma?
Warnings
Does Xolair increase the risk of cancer?
Does Xolair increase the risk of heart attack or stroke?
Can Xolair cause Churg-Strauss syndrome or eosinophilic conditions?
Can patients stop inhaled steroids when starting Xolair for asthma?
Side effects
What are the most common side effects of Xolair for asthma?
“Asthma: In patients ≥12 years of age, the most common adverse reactions (≥1% more frequent in XOLAIR-treated patients) were: arthralgia (8%), pain (general) (7%), leg pain (4%), fatigue (3%), dizziness (3%), fracture (2%), arm pain (2%), pruritus (2%), dermatitis (2%), and earache (2%). In pediatric patients 6 to <12 years of age, the most commonly observed adverse reactions (≥3% more frequent in XOLAIR-treated pediatric patients) were: nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral gastroenteritis, arthropod bites, and epistaxis.” (opens the source at this quote in a new tab)
What side effects do children 6 to 11 have on Xolair?
“The data described below reflect XOLAIR exposure for 926 patients 6 to <12 years of age,
including 583 patients exposed for six months and 292 exposed for one year or more, in
either placebo-controlled or other controlled asthma studies. The mean age of pediatric
patients receiving XOLAIR was 8.8 years; 69% were male, and 64% were Caucasian.
Pediatric patients received XOLAIR 75 mg to 375 mg every 2 or 4 weeks or, for patients
assigned to control groups, standard therapy with or without a placebo. No cases of
malignancy were reported in patients treated with XOLAIR in these trials.
The most common adverse reactions occurring at ≥3% in the pediatric patients receiving
XOLAIR and more frequently than in patients treated with placebo were nasopharyngitis,
headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral
gastroenteritis, arthropod bites, and epistaxis.
The adverse reactions most frequently resulting in clinical intervention (e.g., discontinuation
of XOLAIR, or the need for concomitant medication to treat an adverse event) were
bronchitis (0.2%), headache (0.2%) and urticaria (0.2%). These reactions were observed at
similar rates in XOLAIR-treated patients and control patients.” (opens the source at this quote in a new tab)
How common are Xolair injection site reactions in asthma?
“Injection Site Reactions: In adults and adolescents with asthma, injection site reactions of any severity occurred at a rate of 45% in XOLAIR-treated patients compared with 43% in placebo-treated patients. Severe injection site reactions occurred more frequently in XOLAIR-treated patients compared with patients in the placebo group (12% vs 9%, respectively). The types of injection site reactions in asthma studies included: bruising, redness, warmth, burning, stinging, itching, hive formation, pain, indurations, mass, and inflammation.” (opens the source at this quote in a new tab)